TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease
Christopher H van Dyck, Anja Kahl, Grigor Abelian, Mark Donovan, Manuj Ahuja, David Watson, Rik Ossenkoppele, Takeshi Iwatsubo, Oskar Hansson · 2025
Read TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease by Christopher H van Dyck, Anja Kahl, Grigor Abelian, Mark Donovan, Manuj Ahuja, David Watson, Rik Ossenkoppele, Takeshi Iwatsubo, Oskar Hansson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712654.txt.
Description
Christopher van Dyck and eight co-authors lay out a phase 2 trial of an antibody against Alzheimer's disease in a 2025 paper. The drug, BMS-986446, targets the knotting region of the tau protein, the part that lets toxic tau clumps grow and slip into fresh neurons. Spinal fluid levels of that fragment track the disease's march.
The paper describes the trial's design in early Alzheimer's patients: who joins, what they receive, and how benefit and safety will be judged. Lab work behind the design showed the antibody blocks neurons from swallowing clumped tau as well as its mouse parent did. The trial now tests whether that blockade slows real decline.
Catalog record
| CREATOR | Christopher H van Dyck, Anja Kahl, Grigor Abelian, Mark Donovan, Manuj Ahuja, David Watson, Rik Ossenkoppele, Takeshi Iwatsubo, Oskar Hansson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |